ACRVNasdaqPharmaceutical PreparationsFiscal year ends December 31
Acrivon Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$1.69+0.05 (+3.05%)
Close on Oct 19, 2026
- Market cap
- $70.71M
- P/E (TTM)
- –
- Dividend yield
- –
Acrivon Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Acrivon Therapeutics | Industry median |
|---|---|---|
| Market Cap | $72.42M | $166.30M |
| Enterprise Value | -$17.54M | $88.19M |
| PB Ratio | 0.84 | 2.03 |
| P/TBV Ratio | 0.84 | 2.29 |
Income (trailing twelve months)
| Measure | Acrivon Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$78.37M | -$21.40M |
| Net Income | -$74.23M | -$22.46M |
| EBITDA | -$78.37M | -$16.91M |
| EPS (Diluted) | -$1.88 | -$0.83 |
Returns
| Measure | Acrivon Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -64.6% | -53.2% |
| Return on Assets (ROA) | -57.6% | -40.9% |
| Return on Invested Capital (ROIC) | -5337.5% | -32.4% |
| Return on Capital Employed (ROCE) | -89.4% | -38.1% |
Balance sheet
| Measure | Acrivon Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $89.96M | $61.43M |
| Net Cash (Debt) | $89.96M | $15.35M |
| Net Cash Per Share | $2.10 | $0.66 |
| Equity (Book Value) | $86.67M | $49.09M |
| Book Value Per Share | $2.02 | $1.37 |
| Tangible Book Value | $86.67M | $23.52M |
| Working Capital | $80.05M | $76.81M |
Financial position
| Measure | Acrivon Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 7.99 | 3.34 |
| Quick Ratio | 7.86 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Acrivon Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$62.92M | -$12.35M |
| Capital Expenditures | -$1.22M | -$1.08M |
| Free Cash Flow | -$64.14M | -$20.22M |
| FCF Per Share | -$1.50 | -$0.42 |
Efficiency
| Measure | Acrivon Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.00M | -$703.34K |
| Employee Count | 74 | 74 |
Dividends and yields
| Measure | Acrivon Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -102.5% | -23.3% |
| FCF Yield | -88.6% | -8.72% |
Shares
| Measure | Acrivon Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 42,853,400 | 58,127,000 |
| Shares Change (YoY) | 3.00% | 10.9% |
| Shares Change (QoQ) | 10.6% | 0.54% |
| Float | 16,718,000 | 49,136,700 |
| Shares Held by Insiders | 61.0% | 11.6% |
| Shares Held by Institutions | 49.9% | 59.4% |
Scores
| Measure | Acrivon Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | -2.55 | -0.22 |
| Piotroski F-Score | 2 | 4 |
Calculated by StockData from Acrivon Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.